Home › Castration-Resistant Prostatic Cancer › New York
Castration-Resistant Prostatic Cancer clinical trials in New York
7 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in New York.
Cities in New York
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NYU Langone Hospitals, Brooklyn
- NYU Langone Hospital Long Island, Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07225946Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Northwell Health R.J. Zuckerberg Cancer Hospital, Lake Success
- NYU Langone Health Long Island, Mineola
- NYU Langone Health, New York
- and 3 more
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Oct 29, 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06242470A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Memorial Sloan Kettering Cancer Center ( Site 0006), New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06863272A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Weill Cornell Medicine at New York-Presbyterian, New York
RecruitingPhase 1/2
Ages 18 and older · Men · Updated May 6, 2026 · NCT04868604From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.